IP Verse

Fc-Optimized Anti-Cd25 For Tumour Specific Cell Depletion

Patent No. EP3596123 (titled "Fc-Optimized Anti-Cd25 For Tumour Specific Cell Depletion") was filed by Cancer Research Technology on Mar 13, 2018. The application was issued on Jan 10, 2024.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
PFIZEROct 4, 2024PFIZER

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3596123

CANCER RESEARCH TECHNOLOGY
Application Number
EP18711313A
Filing Date
Mar 13, 2018
Status
Granted And Under Opposition
Dec 8, 2023
Publication Date
Jan 10, 2024
External Links
Slate, Register , Google Patents